MedPath

Relacorilant

Generic Name
Relacorilant
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C27H22F4N6O3S
CAS Number
1496510-51-0
Unique Ingredient Identifier
2158753C7E
Background

Relacorilant is under investigation in clinical trial NCT02804750 (Study to Evaluate CORT125134 in Patients With Cushing's Syndrome).

Associated Conditions
-
Associated Therapies
-
stocktitan.net
·

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients

Corcept Therapeutics submitted an NDA to the FDA for relacorilant, a treatment for hypercortisolism, supported by positive trial results showing efficacy and a superior safety profile.
biospace.com
·

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Cushing’s Syndrome

Corcept Therapeutics submitted an NDA to the FDA for relacorilant, a selective cortisol modulator, to treat Cushing’s syndrome, based on positive trial results showing efficacy and safety without serious adverse events.
etfdailynews.com
·

Corcept Therapeutics Submits New Drug Application for Relacorilant to FDA for Hypercortisolism Treatment

Corcept Therapeutics submitted an NDA to the FDA for relacorilant, a selective cortisol modulator for Cushing’s syndrome, based on positive trial results. Relacorilant showed symptom improvement with a manageable safety profile, lacking major adverse effects of existing therapies. Corcept is also exploring its use in other conditions.
investing.com
·

Corcept files NDA for new Cushing's syndrome drug

Corcept Therapeutics submitted an NDA to the FDA for relacorilant, a treatment for Cushing's syndrome, following positive trial outcomes. The drug shows symptom improvement without common adverse effects. With a strong financial position and a 61.5% stock return over six months, Corcept aims to make relacorilant a standard treatment.

Corcept Therapeutics submits relacorilant new drug application to FDA

Corcept Therapeutics submitted a new drug application to the FDA for relacorilant, a selective cortisol modulator, aimed at treating endogenous hypercortisolism.
morningstar.com
·

Corcept Therapeutics Submits New Drug Application for Cushing's Syndrome Treatment

Corcept Therapeutics has submitted a new drug application to the FDA for relacorilant, a treatment for hypercortisolism (Cushing's syndrome), based on positive trial results showing symptom improvement and acceptable safety. CEO Joseph Belanoff believes it could become the standard care for this condition.

Corcept Therapeutics' Cushing's syndrome therapy shows promise in Phase III trial

Corcept Therapeutics reported positive long-term outcomes from its Phase III study of relacorilant, a treatment for Cushing’s syndrome, showing sustained cardiometabolic improvements and high tolerance over six years. After 24 months, subjects showed significant reductions in mean systolic and diastolic blood pressure, with notable improvements in those switched from placebo. Relacorilant targets the glucocorticoid receptor and is being investigated for various cancers.
finance.yahoo.com
·

Corcept's Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism

Phase 3 study results for relacorilant, treating 116 hypercortisolism patients over up to six years, showed durable cardiometabolic improvements and good tolerability. Significant blood pressure reductions were observed, with relacorilant reversing placebo-induced deterioration and enhancing patient outcomes.
© Copyright 2025. All Rights Reserved by MedPath